Tower Research Capital LLC TRC Has $341,000 Stake in argenx SE (NASDAQ:ARGX)

Tower Research Capital LLC TRC reduced its position in argenx SE (NASDAQ:ARGX - Free Report) by 42.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 555 shares of the company's stock after selling 405 shares during the quarter. Tower Research Capital LLC TRC's holdings in argenx were worth $341,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GeoWealth Management LLC lifted its position in argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in shares of argenx during the fourth quarter worth approximately $37,000. Global Retirement Partners LLC grew its stake in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in shares of argenx in the fourth quarter valued at approximately $38,000. Finally, Jones Financial Companies Lllp raised its position in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Truist Financial reaffirmed a "buy" rating and issued a $700.00 target price (up previously from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Oppenheimer lifted their target price on shares of argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Robert W. Baird increased their price target on argenx from $650.00 to $680.00 and gave the company a "neutral" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. Finally, JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a research note on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, argenx presently has an average rating of "Moderate Buy" and an average target price of $699.28.

argenx Price Performance

argenx stock traded up $6.98 during mid-day trading on Monday, hitting $656.65. 210,611 shares of the company's stock traded hands, compared to its average volume of 309,421. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21. The stock has a market cap of $40.10 billion, a price-to-earnings ratio of -746.19 and a beta of 0.57. The firm has a 50 day simple moving average of $598.32 and a two-hundred day simple moving average of $612.34.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, research analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.